GlassScriptPhysician profile
Aejaz Ul Haq
NPI 1649652595
$8,778.89
in general payments reported to CMS, 2019-2025
33 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $169 · 2022: $1,951 · 2023: $485 · 2024: $5,209 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,599 · Travel and Lodging: $1,861 · Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,598.99 |
| Travel and Lodging | $1,860.67 |
| Food and Beverage | $1,556.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,329.58 | 2024 | |
| Pulmonx Corporation | $1,361.25 | 2024 | Zephyr Endobronchial Valve |
| Ethicon INC. | $1,232.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.58 | 2019-2024 | Ofev |
| Allergan, INC. | $313.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $279.94 | 2019-2024 | Nucala, Arexvy, Trelegy Ellipta |
| United Therapeutics Corporation | $267.08 | 2019-2024 | Orenitram, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $265.92 | 2019-2024 | Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $180.27 | 2022-2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $128.94 | 2019-2025 | Winrevair, Zerbaxa |
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Verona Pharma, INC. | $122.55 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $115.55 | 2023 | Prolastin-C Liquid |
| Insmed, INC. | $105.44 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.30 | 2022-2023 | Glassia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $79.84 | 2022-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $69.76 | 2019-2023 | |
| Genzyme Corporation | $51.72 | 2022-2024 | |
| La Jolla Pharmaceutical Company | $35.38 | 2020 | |
| Portola Pharmaceuticals, LLC | $33.92 | 2019 | |
| Alexion Pharmaceuticals, INC. | $26.89 | 2023 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.88 | 2020 | |
| Inogen, INC. | $23.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.10 | 2022 | |
| Genentech USA, INC. | $20.60 | 2022 | |
| Chiesi USA, INC. | $19.35 | 2019 | |
| Ani Pharmaceuticals, INC. | $19.00 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $18.71 | 2022 | |
| Baxter Healthcare | $18.14 | 2023 | Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $17.12 | 2023 | |
| Jazz Pharmaceuticals INC. | $15.72 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.24 | 2019 | |
| Mylan Specialty L.P. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aejaz Ul Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.